FGFR Gene Alteration clinical trials at UCSD

1 research study open to eligible people

Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
open to eligible people ages 18 years and up
This is an open-label, multinational, randomized Phase 2 study confirming the clinical benefit of 20 mg futibatinib and evaluating the safety and efficacy of 16 mg futibatinib in previously treated CCA harboring FGFR2 gene fusions and other rearrangements.
La Jolla, California and other locations

Last updated: December 4, 2025